Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Kolon TissueGene.

    Client Virtual Booth

    KOLON TISSUEGENE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Kolon TissueGene
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    9713 Key West Ave. Suite 300 Rockville, MD 20850
    Telephone
    Telephone
    +1 (301) 921-6000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tissuegene.com/en_US
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Kolon TissueGene To Expand Indications For TG-C

    Details:

    FDA has allowed the Company to proceed with initiation of a Phase II clinical trial of TG-C(TissueGene-C), an allogeneic cell and gene therapy in osteoarthritis (OA) of the hip.


    Lead Product(s): TissueGene-C

    Therapeutic Area: Musculoskeletal Product Name: TG-C

    Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 03, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Kolon Tissuegene Announces Plans To Resume US Phase III Clinical Trial For TG-C

    Details:

    The trial had been suspended due to product identity concerns. Kolon TissueGene has begun activities to resume the phase III trial and reinitiate enrollment later this year.


    Lead Product(s): TissueGene-C

    Therapeutic Area: Musculoskeletal Product Name: Undisclosed

    Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 13, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search